Local company joins international entity, triples clinical trial opportunities for Central New Yorkers  

lucy wang
Friday, June 24, 2022

Local company joins international entity, triples clinical trial opportunities for Central New Yorkers  

East Syracuse-based Clarity Clinical Research has joined Velocity Clinical Research, the leading international integrated clinical site business. Clarity is now “Velocity Clinical Research Syracuse” after the acquisition at the end of 2021, which has led to an influx of clinical trial opportunities for Central New York. 

As part of a large multi-site network, the number of new trials at the Syracuse site has rocketed to include research on diabetes, COPD, vaccines for flu, Lyme disease, respiratory syncytial virus (RSV). It has also expanded its therapeutic areas to offer nonalcoholic steatohepatitis (NASH) and memory studies, including prevention trials and mild Alzheimer’s disease research. 

Kristen Stebbins, site manager at Velocity Clinical Research Syracuse, shared her excitement about the acquisition, “By centralizing functions like human resources and business development at the national level, our local staff can spend more time with trial volunteers, ensuring they have an optimum experience when taking part in clinical research.”  

Dr. Robert C. Cupelo, principal investigator at Velocity Clinical Research Syracuse, explained why being part a national organization will benefit the local community, “Being able to focus more on patients will speed up how quickly we can develop new drugs. As one of the only clinical research facilities serving Central New York, our growth allows more local residents to get involved in clinical trials to advance medical science. This is particularly vital for individuals with chronic conditions who can now access treatment before it is publicly available.”  

The acquisition has resulted in growth at the site, more than doubling the number of staff and tripling the number of active clinical trials. Velocity Syracuse is currently recruiting volunteer participants for two active studies at no cost: memory loss research and an RSV study. 

Seeking Diverse Participants for Memory Loss Study in Syracuse at No Cost 

A new memory loss study at Velocity Clinical Research Syracuse is seeking a limited number of local adults aged 60 to 80 who are beginning to have problems with their memory or who have suffered from memory problems for several years. In addition, to ensure proper representation across all Central New York’s population, adults aged 65 or older from African American, Hispanic, Asian, and American Indian communities may be eligible to participate in the study even if they are not having trouble with their memory. 

Volunteers will participate in non-invasive memory tests at the Velocity Syracuse Clinic and have a PET scan of their brain at a local imaging facility to detect the potential development of Alzheimer’s disease. These services are now available to participants in Syracuse at no cost. The average cost of receiving a PET scan in the United States is typically $5,750. 

Volunteers will receive the results of their memory test and brain imaging, as well as a stipend for the time and effort participating in the study.  

Opportunity for Older Adults to Join RSV Vaccine Study in Syracuse 

 

This study is for adults aged 60 and older to test the efficacy of a vaccine for respiratory syncytial virus (RSV). There is currently no FDA-approved vaccine for adults to prevent RSV but the development of mRNA technology in response to the COVID-19 pandemic has allowed this trial vaccine to be possible. 

A respiratory virus that usually causes mild, cold-like symptoms, it can be serious and even fatal for infants and older adults. Each year, it is estimated that more than 177,000 older adults are hospitalized and 14,000 of them die in the United States due to RSV infection. Adults at highest risk for severe RSV infection are aged 65 years and older, have a chronic heart or lung disease and weakened immune systems. 

The Phase 3 study is placebo controlled and participants will not know if they receive the active vaccine or not. Volunteers are monitored for two years to understand if they develop symptoms or test positive for RSV. This is a Phase 3 study, meaning the vaccine has already been tested for safety by thousands of volunteers and is now being tested for efficacy to prevent severe complications of RSV as well as the spread to grandchildren and other older adults.  

Participation is at no cost to participants and patients will receive a stipend for the time and effort involved in participating in the study. 

Dr Paul Evans, CEO and President of Velocity, said: “People who participate in clinical trials are heroes. Velocity’s integrated approach to running over 30 sites across the US means we have the capacity to bring opportunities to volunteers on a scale that hasn’t been done before. Ultimately, by recruiting more people to clinical research, we speed up drug development and save more lives.” 

 

###

 

 

About Velocity Clinical Research 

Velocity Clinical Research, headquartered in Durham, NC, is the leading integrated site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. Velocity supports global drug development in primarily conducting phase II and phase III clinical trials. The company has over 30 U.S. locations across 14 states. 

We place the care of the patient at the heart of everything we do. With over 35 years of experience running sites and more than 7000 studies completed, Velocity has refined its patient recruitment strategies while maintaining a focus on delivering timely and reliable data quality. For more information visit our website at https://velocityclinical.com.